Rhone-poulenc Rorer Pharmaceuticals Inc.

Aventis Pharma Deutschland, Gmbh

Aventis Pharmaceuticals Inc.

Henry W Pauls

William R Ewing

Alfred P Spada

Yong Mi Choi-Sledeski

Martin P Maguire

Michael R Becker

Yong-Mi Choi

Michael R Myers

Dilip V Amin

Daniel L Cheney

Jeffrey N Barton

Yong Gong

Daniel Michael Green

Jonathan S Mason

Robert W Studt

Don D Cha

Jonathan Stephen Mason

The compounds of formula I herein exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds

Compounds having antihypertensive, cardioprotective anti-ischemic and antilipolytic properties

Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties

The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More especially, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

Substituted (sulfinic acid, sulfonic acid, sulfonylamino or

The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More especially, they are Factor Xa inhibitors. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of Factor Xa.

This invention relates to a class of novel phosphonate derivatives of lipophilic amines which exhibit squalene synthase inhibition properties. More specifically the compounds are bis aryl cycloalkylamino and azacycloalkyl phosphonates. Compounds of this invention reduce levels of serum cholesterol in the body without significantly reducing mevalonic metabolite synthesis. This invention relates also to pharmacological compositions and method of treatment for lowering serum cholesterol levels using the compounds of this invention.

Phosphonate derivatives of lipophilic amines

This invention relates to a class of novel dicarboxy amide derivatives of lipophilic amines which exhibit squalene synthase inhibition properties. More specifically the compounds are bis-aryl and/or heteroaryl alkyl or cycloalkylamino dicarboxy amides. Compounds of this invention reduce levels of serum cholesterol in the body without significantly reducing mevalonic metabolite synthesis. This invention relates also to pharmacological compositions and method of treatment for lowering serum cholesterol levels using the compounds of this invention.

Polyarylcarbamoylaza- and -carbamoylalkanedioic acids

Growing community of inventors

Collegeville, PA, United States of America

Henry W Pauls